Rapid Evaluation of Amantadine for Treatment of Cocaine Abuse/Dependence - 4

Sponsor

University of California, Los Angeles (Other)

Overall Status

Completed

CT.gov ID

NCT00000301

Collaborator

National Institute on Drug Abuse (NIDA) (NIH)

Enrollment

Location

Study Details

Study Description

Brief Summary

The purpose of this study is to empirically test a series of medications to: 1) determine each medication's efficacy in treatment of cocaine abuse/dependence; 2) find most effective dose range for each medication. In this study, amantadine is tested."

Condition or Disease	Intervention/Treatment	Phase
Cocaine-Related Disorders	Drug: Amantadine	Phase 2

Detailed Description

16-week participation plus a 2 weekk lead-in period. Participants are assigned randomly to placebo or amantadine. Participants attend group meeting 3 times/week

Study Design

Study Type:

Interventional

Allocation:

Randomized

Masking:

Double

Primary Purpose:

Treatment

Official Title:

Rapid Evaluation of Cocaine Pharmacotherapies (Amantadine)

Study Start Date :

Mar 1, 1996

Actual Primary Completion Date :

Jun 1, 1998

Outcome Measures

Primary Outcome Measures

Retention []
Cocaine use []
Cocaine craving []
Psychosocial progress []

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

M/F, ages 18-65. cocaine dependence according to DMS-IV criteria. Self-reported use within the last 30 days. Agreeable to conditions of the study and signed informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy, history of seizures. Pregnant and/or nursing women. Dependence on ETOH or benzodiazepines or other sedative-hypnotics. Acute hepatitis. Other medical conditions that deem participation to be unsafe.